Replies to post #138830 on Biotech Values

[turtlepower]

ECYT - I think it's still undervalued. Perhaps some are taking profits. The EV is about 60M when debt is taken into account. I suppose when you compare to similar companies like THLD, SNTA or INFI it's cheap. It's a wholly owned program and they have a pipeline of linkers and payloads. So they have the opportunity to partner and I hope they do that. Also the assumption is that there is a lack of catalysts until late 2013 but they are presenting at AACR in a few weeks and probably the most interesting presentation could be the late breaker.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=783edb67-9fbe-4b38-81c5-4b7f74b27171&cKey=8d83b352-380b-4cd5-880f-5ece93aa8c02&mKey=%7b2D8C569E-B72C-4E7D-AB3B-070BEC7EB280%7d